Therapeutic effect of lipoprostaglandin E1 on sudden hearing loss

Am J Otolaryngol. 2005 Jul-Aug;26(4):245-8. doi: 10.1016/j.amjoto.2005.01.009.

Abstract

Purpose: The authors conducted a prospective, comparative clinical trial for the purpose of additional effect of lipoprostaglandin E 1 (lipo-PGE 1 ) on sudden hearing loss.

Materials and methods: With the approval of the institute ethics committee, a total of 128 consecutive patients with diagnoses of sudden hearing loss were included in the study. The patients in the lipo-PGE 1 group received continuous infusion of 10 microL lipo-PGE 1 and 48 mg methylprednisolone for 5 days, and the patient in the control group were treated with only 48 mg methylprednisolone.

Results: The total recovery rate after the treatment was 67.2%. There were 70.5% recovery rate in lipo-PGE 1 group and 60.5% recovery rate in control group. However, no significant differences were observed in the improvements of pure tone average and subjective symptoms between the lipo-PGE 1 and control groups.

Conclusion: The results failed to prove a beneficial effect of lipo-PGE 1 in the treatment of sudden hearing loss in spite of its higher cure rate.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Alprostadil / administration & dosage
  • Alprostadil / pharmacology
  • Alprostadil / therapeutic use*
  • Anti-Inflammatory Agents / administration & dosage
  • Audiometry, Pure-Tone
  • Auditory Threshold / drug effects*
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Hearing Loss, Sudden / drug therapy*
  • Humans
  • Infusions, Intralesional
  • Male
  • Methylprednisolone / administration & dosage
  • Middle Aged
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / pharmacology
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Prospective Studies
  • Tinnitus
  • Treatment Outcome
  • Vasodilator Agents / administration & dosage
  • Vasodilator Agents / pharmacology
  • Vasodilator Agents / therapeutic use*
  • Vertigo

Substances

  • Anti-Inflammatory Agents
  • Platelet Aggregation Inhibitors
  • Vasodilator Agents
  • Alprostadil
  • Methylprednisolone